Gyeongseo Yoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gyeongseo Yoo has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Boyoung Joung
Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
3 shared publications Ji-Young Kang
3 shared publications- Malgeum Park
Division of Cardiology, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea
3 shared publications Dasom Mun
Division of Cardiology, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea
2 shared publicationsJaewoong Lee
Division of Cardiology, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea
2 shared publicationsNuri Yun
2 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Elsevier in Materials Today Bio
- Vol. 41
Reprogrammed macrophage-derived nanovesicle–lipid nanoparticle hybrids for cardiac siRUNX1 delivery: Therapeutic evaluation in Ang II-induced cardiac remodeling
- 31 October 2026
- Published by Elsevier in Materials Today Bio
- Vol. 41
Open AccessReprogrammed macrophage-derived nanovesicle–lipid nanoparticle hybrids for cardiac siRUNX1 delivery: Therapeutic evaluation in Ang II-induced cardiac remodeling
- Open Access
- 8 August 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 222, 537-552
Magnetically guided apoptotic mesenchymal stem cell-derived nanovesicles for the modulation of pathological remodeling in cardiac injury
- 8 August 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 222, 537-552
Open AccessMagnetically guided apoptotic mesenchymal stem cell-derived nanovesicles for the modulation of pathological remodeling in cardiac injury
- Open Access
- 23 April 2026
- Published by Elsevier in SSRN Electronic Journal
Magnetically Guided Apoptotic Mesenchymal Stem Cell-Derived Nanovesicles for Modulating Pathological Remodeling in Cardiac Injury
Inflammation and fibrosis can arise as consequences of cardiac injury and further contribute to the progression of heart failure (HF) and arrhythmias. Despite ongoing therapeutic advancements, effective treatments to modulate these pathological processes remain limited. To overcome these limitations, a novel nanotherapeutic system using apoptotic mesenchymal stem cell-derived nanovesicles (ANV) as biocompatible and immunomodulatory delivery platforms for small interfering RNA (siRNA) targeting the adipocyte enhancer binding protein 1 (AEBP1) gene is developed. ANV are constructed via an extrusion method and loaded with AEBP1-targeting siRNA (siAEBP1) through electroporation to form ANV-siAEBP1. The vesicles are then incubated with antibody-conjugated iron oxide magnetic nanoparticles (MNP), forming the ANVP-siAEBP1 complex. For targeted delivery to the injured myocardium, an anti-myosin light chain 3 (MLC3) antibody is incorporated, based on injury-associated MLC3 exposure for localized accumulation of ANVP-siAEBP1 at the injury site. Upon localization, intracellular release of siAEBP1, silences AEBP1 expression, downregulates pro-fibrotic signaling, and mitigates cardiac fibrosis. Simultaneously, the intrinsic anti-inflammatory effects of ANV prevent excessive inflammatory responses. This dual mechanism of action results in synergistic therapeutic effects, significantly attenuating both inflammation and fibrosis with enhanced targeting efficiency. Collectively, this engineered four-in-one nanovesicle platform offers a promising strategy for next-generation precision therapeutics in cardiac injury.
- 23 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMagnetically Guided Apoptotic Mesenchymal Stem Cell-Derived Nanovesicles for Modulating Pathological Remodeling in Cardiac Injury
Inflammation and fibrosis can arise as consequences of cardiac injury and further contribute to the progression of heart failure (HF) and arrhythmias. Despite ongoing therapeutic advancements, effective treatments to modulate these pathological processes remain limited. To overcome these limitations, a novel nanotherapeutic system using apoptotic mesenchymal stem cell-derived nanovesicles (ANV) as biocompatible and immunomodulatory delivery platforms for small interfering RNA (siRNA) targeting the adipocyte enhancer binding protein 1 (AEBP1) gene is developed. ANV are constructed via an extrusion method and loaded with AEBP1-targeting siRNA (siAEBP1) through electroporation to form ANV-siAEBP1. The vesicles are then incubated with antibody-conjugated iron oxide magnetic nanoparticles (MNP), forming the ANVP-siAEBP1 complex. For targeted delivery to the injured myocardium, an anti-myosin light chain 3 (MLC3) antibody is incorporated, based on injury-associated MLC3 exposure for localized accumulation of ANVP-siAEBP1 at the injury site. Upon localization, intracellular release of siAEBP1, silences AEBP1 expression, downregulates pro-fibrotic signaling, and mitigates cardiac fibrosis. Simultaneously, the intrinsic anti-inflammatory effects of ANV prevent excessive inflammatory responses. This dual mechanism of action results in synergistic therapeutic effects, significantly attenuating both inflammation and fibrosis with enhanced targeting efficiency. Collectively, this engineered four-in-one nanovesicle platform offers a promising strategy for next-generation precision therapeutics in cardiac injury.